MACH7 TECHNOLOGIES LIMITED — Investor Presentation 2018

Jul 30, 2018

CEO Presentation Mach7 Technologies Limited (ASX:M7T) General Meeting of Shareholders 31 July 2018

MIKE JACKMAN

Copyright © 2018 Mach7 Technologies

Disclaimer

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“ M7T ”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

TODAY’S MESSAGES WE HAVE A STRONG VALUE PROPOSITION FOR:

Our Customers:

• Delivering improved clinical, business and operational outcomes

• Addressing new market entries with Mach7 Data Services Platform for healthcare

• Investing in innovation to convert data into meaningful insight for better patient outcomes

• Increasing applications integrated with Mach7 platform through partnerships

Our Shareholders:

• Improving the quantity and the quality of the sales pipeline

• Expanding addressable markets and focusing on market share growth in core USA market

• Growing number of customers and increasing contracted annual recurring revenue (CARR) +24% on FY17

==> picture [1152 x 109] intentionally omitted <==

MACH7 MISSION

Mach7 interoperable solutions improve business, operational and clinical outcomes delivering meaningful insight where and when it is needed.

MACH7 EVOLUTION

==> picture [86 x 80] intentionally omitted <==

==> picture [62 x 60] intentionally omitted <==

==> picture [1117 x 115] intentionally omitted <==

----- Start of picture text -----

2007 2010 2012 2016 2018
Mach7 Founded
- First commercial wins M7T listed in ASX - PACS replacement market
First pilots deployed
- Revenue phase begins - Launch v12
----- End of picture text -----

Growing our addressable Enterprise Imaging (VNA) market through portfolio Market ~ 600 M and market expansion

Enterprise Imaging & PACS replacement market ~ 3.9B Data Services Platform: v12

MACH7 UNMATCHED VALUE PROPOSITION

Delivering clinical, business and operational improvements, resulting in lower costs, increased efficiencies and improved patient care.

A proven unique and innovative platform that enables access, interoperability, and liquidity of your clinical data.

Outcome examples:

==> picture [247 x 98] intentionally omitted <==

----- Start of picture text -----

Reduce
redundant
technology Lower Per
contracts and procedure costs
service
agreements
----- End of picture text -----

==> picture [245 x 98] intentionally omitted <==

----- Start of picture text -----

Requires less time Requires less
and effort to infrastructure to
setup and deploy and
configure operate
----- End of picture text -----

==> picture [553 x 263] intentionally omitted <==

CORE INTELLECTUAL PROPERTY

A Data Services Platform that simplifies the consolidation, replacement, and adoption of technologies that enhance clinical outcomes.

Sage delivers a standards based interface for clinical apps to access and exchange patient data from across enterprise data sources. The result is the liquidity of patient data, the reduction of redundant technologies, and the ability to replace underlying technologies at a lower cost without disrupting patient care.

==> picture [775 x 364] intentionally omitted <==

GROWING CUSTOMER BASE

Mach7’s global customer base is progressing from earlier adopters towards significantly larger mid-market

==> picture [207 x 61] intentionally omitted <==

==> picture [112 x 63] intentionally omitted <==

==> picture [263 x 67] intentionally omitted <==

==> picture [186 x 28] intentionally omitted <==

healthcare systems (across hundreds of sites)

==> picture [139 x 62] intentionally omitted <==

==> picture [123 x 48] intentionally omitted <==

==> picture [233 x 50] intentionally omitted <==

==> picture [241 x 53] intentionally omitted <==

==> picture [113 x 48] intentionally omitted <==

==> picture [182 x 44] intentionally omitted <==

==> picture [138 x 33] intentionally omitted <==

==> picture [134 x 32] intentionally omitted <==

==> picture [135 x 72] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [134 x 46] intentionally omitted <==

==> picture [107 x 49] intentionally omitted <==

==> picture [85 x 40] intentionally omitted <==

==> picture [154 x 61] intentionally omitted <==

==> picture [198 x 40] intentionally omitted <==

==> picture [183 x 53] intentionally omitted <==

==> picture [150 x 55] intentionally omitted <==

==> picture [98 x 36] intentionally omitted <==

==> picture [204 x 36] intentionally omitted <==

==> picture [190 x 44] intentionally omitted <==

==> picture [159 x 28] intentionally omitted <==

Early customers – academic medical centres and large integrated delivery networks

Mid-market opportunities – mid-market adoption of VNA technology increasingly dominating Mach7’s customer focus

STRATEGY TO WIN

==> picture [476 x 87] intentionally omitted <==

==> picture [1024 x 481] intentionally omitted <==

----- Start of picture text -----

Innovative healthcare data
services, intelligent platform &
reconstructed PACS
Disrupt the
market
New regions
through indirect
channels, VAR, and •
Growing the app ecosystem
OEM partners
•
Grow New application verticals on
Enter new the platform
through
•
markets partnerships Technology partners
Customer
Innovative workflow
improvement
Focus on customer outcomes,
services
clinical improvements, revenue
Solve the
growth and internal cost efficiency
Improved
common
outcomes
problems
----- End of picture text -----

THANK YOU

Copyright © 2018 Mach7 Technologies